vs
Acadian Asset Management Inc.（AAMI）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Acadian Asset Management Inc.的1.2倍（$207.3M vs $172.2M），Acadian Asset Management Inc.净利率更高（20.2% vs -62.0%，领先82.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 2.6%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 27.6%）
Acadian Asset Management Inc.是一家总部位于美国马萨诸塞州波士顿的资产管理机构，专注于为全球机构及个人客户提供专业的投资管理解决方案，在资产管理领域拥有成熟的服务经验与市场布局。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
AAMI vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $172.2M | $207.3M |
| 净利润 | $34.7M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 33.3% | -54.7% |
| 净利率 | 20.2% | -62.0% |
| 营收同比 | 2.6% | 25.9% |
| 净利润同比 | -18.4% | 3.5% |
| 每股收益（稀释后） | $0.97 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $172.2M | $207.3M | ||
| Q3 25 | $144.2M | $159.9M | ||
| Q2 25 | $127.4M | $166.5M | ||
| Q1 25 | $119.9M | $139.3M | ||
| Q4 24 | $167.8M | $164.6M | ||
| Q3 24 | $123.1M | $139.5M | ||
| Q2 24 | $109.0M | $147.0M | ||
| Q1 24 | $105.7M | $108.8M |
| Q4 25 | $34.7M | $-128.6M | ||
| Q3 25 | $15.1M | $-180.4M | ||
| Q2 25 | $10.1M | $-115.0M | ||
| Q1 25 | $20.1M | $-151.1M | ||
| Q4 24 | $42.5M | $-133.2M | ||
| Q3 24 | $16.9M | $-133.5M | ||
| Q2 24 | $11.0M | $-131.6M | ||
| Q1 24 | $14.6M | $-170.7M |
| Q4 25 | 33.3% | -54.7% | ||
| Q3 25 | 18.4% | -106.9% | ||
| Q2 25 | 12.7% | -64.8% | ||
| Q1 25 | 26.6% | -102.6% | ||
| Q4 24 | 38.7% | -74.3% | ||
| Q3 24 | 21.9% | -94.6% | ||
| Q2 24 | 18.9% | -79.1% | ||
| Q1 24 | 21.7% | -151.9% |
| Q4 25 | 20.2% | -62.0% | ||
| Q3 25 | 10.5% | -112.8% | ||
| Q2 25 | 7.9% | -69.0% | ||
| Q1 25 | 16.8% | -108.5% | ||
| Q4 24 | 25.3% | -80.9% | ||
| Q3 24 | 13.7% | -95.7% | ||
| Q2 24 | 10.1% | -89.5% | ||
| Q1 24 | 13.8% | -156.8% |
| Q4 25 | $0.97 | $-1.28 | ||
| Q3 25 | $0.42 | $-1.81 | ||
| Q2 25 | $0.28 | $-1.17 | ||
| Q1 25 | $0.54 | $-1.57 | ||
| Q4 24 | $1.11 | $-1.34 | ||
| Q3 24 | $0.45 | $-1.40 | ||
| Q2 24 | $0.29 | $-1.52 | ||
| Q1 24 | $0.37 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | $200.0M | — |
| 股东权益账面价值 | — | $-80.0M |
| 总资产 | $677.0M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $200.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $275.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-80.0M | ||
| Q3 25 | — | $9.2M | ||
| Q2 25 | — | $151.3M | ||
| Q1 25 | — | $144.2M | ||
| Q4 24 | — | $255.0M | ||
| Q3 24 | — | $346.8M | ||
| Q2 24 | — | $432.4M | ||
| Q1 24 | — | $140.3M |
| Q4 25 | $677.0M | $1.5B | ||
| Q3 25 | $751.4M | $1.2B | ||
| Q2 25 | $672.3M | $1.3B | ||
| Q1 25 | $677.3M | $1.3B | ||
| Q4 24 | $703.2M | $1.5B | ||
| Q3 24 | $555.2M | $1.5B | ||
| Q2 24 | $533.1M | $1.6B | ||
| Q1 24 | $544.9M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | -0.07× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-2.4M | $-99.8M | ||
| Q3 25 | $-23.9M | $-91.4M | ||
| Q2 25 | $61.6M | $-108.3M | ||
| Q1 25 | $-48.8M | $-166.5M | ||
| Q4 24 | $55.8M | $-79.3M | ||
| Q3 24 | $69.6M | $-67.0M | ||
| Q2 24 | $45.7M | $-77.0M | ||
| Q1 24 | $-40.4M | $-190.7M |
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
| Q4 25 | -0.07× | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | 6.10× | — | ||
| Q1 25 | -2.43× | — | ||
| Q4 24 | 1.31× | — | ||
| Q3 24 | 4.12× | — | ||
| Q2 24 | 4.15× | — | ||
| Q1 24 | -2.77× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AAMI
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
